Quantum量子訊息有限公司
← 最新全球產業報告

Lung Cancer Diagnostic and Screening Market

研究執行與發布:Coherent Market Insights · 發布日期 2026-07-01 · 258 頁
由量子訊息有限公司(Quantum Information)在台灣代理銷售與提供授權諮詢。

2026 年市場規模
USD 3,287.8 Mn
2033 年預估規模
USD 6,530.4 Mn
年複合成長率 CAGR
10.3%

以上數字由 Coherent Market Insights 於本報告中提出,量子訊息原樣引用。

出版商 Coherent Market Insights產業別 Healthcare & Life Sciences出版日期 2026-07-01頁數 258報告編號 CMI4434

授權報價

Single User Price$4,500 USD
Enterprise License$10,000 USD
洽詢購買 申請 Sample
完整報告名稱與涵蓋範圍
Lung Cancer Diagnostic and Screening Market, By Test Type (Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others) Imaging Test (Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy), By Cancer Type (Non-small cell lung cancer, Small Cell Lung Cancer Neurosurgery), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

Lung cancer begins in the lungs and may spread to lymph nodes or other organs in the body, such as the brain. Cancer from other organs also may spread to the lungs. When cancer cells spread from one organ to another, they are called metastases. Lung cancers usually are grouped into two main types such as small cell and non-small cell. These types of lung cancer grow differently and are treated differently. According American Cancer Society non-small cell lung cancer is more common than small cell lung cancer. Different people have different symptoms for lung cancer. Some people have symptoms related to the lungs. Some people whose lung cancer has spread to other parts of the body (metastasized) have symptoms specific to that part of the body. Lung cancer symptoms may include coughing that gets worse or prolonged coughing, chest pain, shortness of breath, wheezing, coughing of blood, feeling very tired all the time, weight loss with no known cause. According to the Centers for Disease Control and Prevention, lung cancer is the third most common cancer in the U.S. Most people in the U.S. die from lung cancer than any other type of cancer. For instance, According American Cancer Society, an estimated 154,050 Americans were expected to die from lung cancer in 2018, accounting for approximately 25% of all cancer deaths. Doctors may perform several tests to confirm lung cancer such as biomarker test, imaging test, and biopsy. Market Dynamics Regulatory approvals and launches of new screening test are expected to propel growth of the global lung cancer diagnostic and screening market during the forecast period. For instance, in August 2020, the U.S. Food and Drug Administration approved the liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC). However, high cost of lung cancer screening test is also expected to limit the market growth. For instance, according to the American Board of International medicine a CT scan costs US$ 300 and more. These test one need to take periodically. Key features of the study • This report provides in-depth analysis of the global lung cancer diagnostic and screening market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026-2033, considering 2025 as the base year • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players • It profiles key players in the global lung cancer diagnostic and screening market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies • Key players covered as a part of this study include Abbott, Illumina, Inc, Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics, Inc. F. Hoffmann-La Roche Ltd., Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc. • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics • The global lung cancer diagnostic and screening market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for lung cancer diagnostic and screening market, research and consulting firms, new entrants, and financial analysts. Market Segmentation • By Test Type o Biomarkers Test  EGFR Mutation Test  KRAS Mutation Test  ALK Test  HER2 Test  Others o Imaging Test  Computed Tomography (CT) scan  Positron Emission Tomography (PET) scan  Chest X-Ray  Others o Biopsy • By Cancer Type o Non-small cell lung cancer o Small Cell Lung Cancer Neurosurgery • By End User o Hospital Associated Labs o Independent Diagnostic Laboratories o Cancer Research Institutes o Others • By Region o North America  U.S.  Canada o Latin America  Brazil  Mexico  Argentina  Rest of Latin America o Europe  Germany  U.K.  France  Italy  Spain  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC  Israel  Rest of Middle East o Africa  South Africa  Central Africa  North Africa • Competitive Landscape o Abbott o Amgen Inc. o Illumina, Inc. o Thermo Fisher Scientific Inc. o Lepu Medical Technology (Beijing)Co.,Ltd. o AstraZeneca o Hoffmann-La Roche Ltd o Laboratory Corporation of America Holdings. o Agilent Technologies, Inc. o QIAGEN o Quest Diagnostics Incorporated. o NeoGenomics Laboratories. o Myriad Genetics, Inc. o GRAIL, LLC. o DELFI Diagnostics
目錄 Table of Contents
Table of Contents 1. Research Objective and Assumption o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snippet, By Test Type  Market Snippet, By Cancer Type  Market Snippet, By End User  Market Snippet, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Impact Analysis o Recent Test Launches o Epidemiology o Merger, Acquisition, and Collaborations o Regulatory Scenario o Key Developments o PEST Analysis 4. Global Lung Cancer Diagnostic and Screening Market, By Test Type, 2021–2033, (US$ Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022–2033  Segment Trends o Biomarkers Test  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (US$ Mn)  Segment Trends o EGFR Mutation Test o KRAS Mutation Test o ALK Test o HER2 Test o Others o Imaging Test  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (US$ Mn)  Segment Trends o Computed Tomography (CT) scan o Positron Emission Tomography (PET) scan o Chest X-Ray o Others o Biopsy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (US$ Mn)  Segment Trends 5. Global Lung Cancer Diagnostic and Screening Market, By Cancer Type, 2021–2033, (US$ Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022–2033  Segment Trends o Non-small cell lung cancer  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (US$ Mn)  Segment Trends o Small Cell Lung Cancer  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (US$ Mn)  Segment Trends 6. Global Lung Cancer Diagnostic and Screening Market, By End User, 2021–2033, (US$ Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022–2033  Segment Trends o Hospital Associated Labs  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (US$ Mn) o Independent Diagnostic Laboratories  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (US$ Mn) o Cancer Research Institutes  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (US$ Mn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (US$ Mn) 7. Global Lung Cancer Diagnostic and Screening Market, By Region, 2021–2033, (US$ Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022–2033  Segment Trends o North America  Introduction  Market Size and Forecast, Y-o-Y Growth and By Test Type, 2021 –2033, (US$ Mn)  Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2021 –2033, (US$ Mn)  Market Size and Forecast, Y-o-Y Growth and By End User, 2021–2033, (US$ Mn)  Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 –2033, (US$ Mn) o U.S. o Canada o Europe  Introduction  Market Size and Forecast,Y-o-Y Growth and By Test Type, 2021 –2033, (US$ Mn)  Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2021 –2033, (US$ Mn)  Market Size and Forecast,Y-o-Y Growth and By End User, 2021–2033, (US$ Mn)  Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 –2033, (US$ Mn) o U.K. o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast,Y-o-Y Growth and By Test Type, 2021 –2033, (US$ Mn)  Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2021 –2033, (US$ Mn)  Market Size and Forecast,Y-o-Y Growth and By End User, 2021–2033, (US$ Mn)  Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 –2033, (US$ Mn) o China o India o Japan o ASEAN o Australia o South Korea o Rest of Asia Pacific o Latin America  Introduction  Market Size and Forecast,Y-o-Y Growth and By Test Type, 2021 –2033, (US$ Mn)  Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2021 –2033, (US$ Mn)  Market Size and Forecast,Y-o-Y Growth and By End User, 2021–2033, (US$ Mn)  Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 –2033, (US$ Mn) o Brazil o Mexico o Argentina o Rest of Latin America o Middle East  Introduction  Market Size and Forecast,Y-o-Y Growth and By Test Type, 2021 –2033, (US$ Mn)  Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2021 –2033, (US$ Mn)  Market Size and Forecast,Y-o-Y Growth and By End User, 2021–2033, (US$ Mn)  Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 –2033, (US$ Mn) o GCC o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast,Y-o-Y Growth and By Test Type, 2021 –2033, (US$ Mn)  Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2021 –2033, (US$ Mn)  Market Size and Forecast,Y-o-Y Growth and By End User, 2021–2033, (US$ Mn)  Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 –2033, (US$ Mn) o North Africa o Central Africa o South Africa 8. Competitive Landscape o Company Profiles  Abbott o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies  Amgen Inc. o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies  Illumina, Inc. o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies  Thermo Fisher Scientific Inc. o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies  Lepu Medical Technology(Beijing)Co.,Ltd. o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies  AstraZeneca o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies  F. Hoffmann-La Roche Ltd o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies  Laboratory Corporation of America Holdings. o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies  Agilent Technologies, Inc. o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies  QIAGEN o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies  Quest Diagnostics Incorporated. o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies  NeoGenomics Laboratories. o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies  Myriad Genetics, Inc. o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies  GRAIL, LLC. o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies  DELFI Diagnostics o Company Overview o Product Portfolio o Key Highlights o Financial Overview o Strategies 9. Section o References o Research Methodology o About us and Sales Contact

提及公司

AbbottAmgen Inc.Illumina, Inc.Thermo Fisher Scientific Inc.Lepu Medical Technology (Beijing)Co.,Ltd.AstraZenecaHoffmann-La Roche LtdLaboratory Corporation of America Holdings.Agilent Technologies, Inc.QIAGENQuest Diagnostics Incorporated.NeoGenomics Laboratories.Myriad Genetics, Inc.GRAIL, LLC.DELFI Diagnostics

同分類最新報告(醫療與生命科學)

常見問題

這份報告可以先索取樣本嗎?

可以。建議購買前先申請樣本,提出申請後約 2 個工作天內提供,您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算?

報告以美元標價,台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本(單人/多人/企業全站)價格不同,量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付?如何付款?

一般 3–7 個工作天交付,實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票,30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們